中低收入国家药物警戒:以非洲为重点的综述
本综述总结了中低收入国家(LMIC)在建立药物警戒系统方面的特殊挑战与进展,重点关注非洲。文章指出,尽管部分区域经济共同体努力协调药物警戒法规,但系统整合度与可靠性有限,且面临报告工具本地化翻译困难、医护人员相对患者数量不足、草药与传统药物自我药疗普遍、政治冲突、药品利用数据缺乏、训练有素人员稀缺、预算支持不足、人员流动率高、医护人员与决策者及消费者意识薄弱、公共卫生项目与国家药品监管机构协作不足等问题。自发报告率极低且报告质量差,阻碍了稳健的信号检测分析。
要点
- LMIC药物警戒系统整合度与可靠性有限,报告工具本地化翻译困难。
- 草药与传统药物自我药疗普遍,药品利用数据缺乏,难以可靠估计药物风险。
- 自发报告率极低且质量差,阻碍信号检测;人员与预算支持严重不足。
核心结论
- LMIC建立稳健药物警戒系统面临多重特殊挑战,非洲情况尤为突出,需系统性应对以生成可指导卫生政策与实践的数据。
研究设计与样本
- 综述类文章,总结LMIC药物警戒的具体挑战与进展领域,特别聚焦非洲。
主要发现
- LMIC药物警戒系统整合度与可靠性有限,尽管多个区域经济共同体已努力协调法规。
- 报告工具需翻译成多种本地语言,且医护人员相对患者数量少、咨询时间极短。
- 草药与传统药物自我药疗摄入率高,政治冲突危及脆弱系统,药品利用数据几乎或完全不可及。
- 训练有素人员稀缺,国家政府预算支持少或无,药物警戒人员流动率高且培训耗费大量资源。
- 医护人员、决策者与消费者对药物警戒意识薄弱;公共卫生项目与国家药品监管机构协作少。
临床怎么用
- 临床药学智能体应关注LMIC患者草药与传统药物自我药疗的潜在风险与相互作用。
- 在LMIC环境下应重视自发报告质量提升与医护人员药物警戒意识培养。
- 需结合当地药品利用数据可及性有限的实际,谨慎解读药物风险信号。
局限性
- 本文为综述,未报告原始研究的具体样本量、效应量或统计学检验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Low- and middle-income countries (LMIC) face unique challenges with regard to the establishment of robust pharmacovigilance systems capable of generating data to inform healthcare policy and practice. These include the limited integration and reliability of pharmacovigilance systems across LMIC despite recent efforts to harmonize pharmacovigilance rules and regulations in several regional economic communities. There are particular challenges relating to the need to translate reporting tools into numerous local languages and the low numbers of healthcare providers relative to number of patients, with very short consultation times. Additional factors frequent in LMIC include high uptake of herbal and traditional medication, mostly by self-medication; disruptive political conflicts jeopardizing fragile systems; and little or no access to drug utilization data, which makes it difficult to reliably estimate the true risks of medicines use. Pharmacovigilance activities are hindered by the scarcity of well-trained personnel with little or no budgetary support from national governments; high turnover of pharmacovigilance staff whose training involves a substantial amount of resources; and little awareness of pharmacovigilance among healthcare workers, decision makers and consumers. Furthermore, little collaboration between public health programmes and national medicines regulatory authorities coupled with limited investment in pharmacovigilance activities, especially during mass drug administration for neglected tropical diseases and mass vaccinations, produces major challenges in establishing a culture where pharmacovigilance is systematically embedded. Very low spontaneous reporting rates with poor quality reports hinders robust signal detection analyses. This review summarises the specific challenges and areas of progress in pharmacovigilance in LMIC with special focus on the situation in Africa.
引用
- Kiguba R, Olsson S, Waitt C, et al. Pharmacovigilance in low- and middle-income countries: A review with particular focus on Africa. Br J Clin Pharmacol. 2022. PMID: 34937122. doi:10.1111/bcp.15193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。